Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients

Sven F Seys, Hans Scheers, Paul Van den Brande, Gudrun Marijsse, Ellen Dilissen, Annelies Van Den Bergh, Pieter C Goeminne, Peter W Hellings, Jan L Ceuppens, Lieven J Dupont, Dominique M A Bullens, Sven F Seys, Hans Scheers, Paul Van den Brande, Gudrun Marijsse, Ellen Dilissen, Annelies Van Den Bergh, Pieter C Goeminne, Peter W Hellings, Jan L Ceuppens, Lieven J Dupont, Dominique M A Bullens

Abstract

Background: Asthma is characterized by a heterogeneous inflammatory profile and can be subdivided into T(h)2-high and T(h)2-low airway inflammation. Profiling of a broader panel of airway cytokines in large unselected patient cohorts is lacking.

Methods: Patients (n = 205) were defined as being "cytokine-low/high" if sputum mRNA expression of a particular cytokine was outside the respective 10th/90th percentile range of the control group (n = 80). Unsupervised hierarchical clustering was used to determine clusters based on sputum cytokine profiles.

Results: Half of patients (n = 108; 52.6%) had a classical T(h)2-high ("IL-4-, IL-5- and/or IL-13-high") sputum cytokine profile. Unsupervised cluster analysis revealed 5 clusters. Patients with an "IL-4- and/or IL-13-high" pattern surprisingly did not cluster but were equally distributed among the 5 clusters. Patients with an "IL-5-, IL-17A-/F- and IL-25- high" profile were restricted to cluster 1 (n = 24) with increased sputum eosinophil as well as neutrophil counts and poor lung function parameters at baseline and 2 years later. Four other clusters were identified: "IL-5-high or IL-10-high" (n = 16), "IL-6-high" (n = 8), "IL-22-high" (n = 25). Cluster 5 (n = 132) consists of patients without "cytokine-high" pattern or patients with only high IL-4 and/or IL-13.

Conclusion: We identified 5 unique asthma molecular phenotypes by biological clustering. Type 2 cytokines cluster with non-type 2 cytokines in 4 out of 5 clusters. Unsupervised analysis thus not supports a priori type 2 versus non-type 2 molecular phenotypes. www.clinicaltrials.gov NCT01224938. Registered 18 October 2010.

Keywords: Airway inflammation; Endotype; Phenotype; Precision medicine; Type 2 inflammation.

Figures

Fig. 1
Fig. 1
Absolute sputum cytokine levels among different clusters of asthmatics. Patients were clustered based on their sputum cytokine-high or cytokine-low profile. Asthmatics are divided into 5 clusters: cluster 1: n = 24, IL-5-high and IL-17 F-high; cluster 2: n = 15, IL-5-high and IL-17 F-low; cluster 3: n = 8, IL-6-high; cluster 25: n = 15, IL-22-high; cluster 5: n = 132. Absolute sputum cytokine levels were shown as 10-90th percentile box and whiskers plots. The dotted line represents the 10th or 90th percentile value of control individuals
Fig. 2
Fig. 2
Lung function and airway inflammatory parameters. Asthmatics are divided into 5 clusters: cluster 1: n = 24, IL-5-high and IL-17 F-high; cluster 2: n = 15, IL-5-high and IL-17 F-low; cluster 3: n = 8, IL-6-high; cluster 25: n = 15, IL-22-high; cluster 5: n = 132. Data are represented as mean ± standard deviation (a-c) or median ± interquartile range (d-f). Data are compared between the 5 clusters by Kruskal-Wallis and Dunn’s Multiple comparison test (∞: p < 0.05). Data of each cluster was compared to the mean (a-c) or median (d-f) of the total group (*: p < 0.05, **:p < 0.01; ***:p < 0.001)
Fig. 3
Fig. 3
Decision tree with patient clusters of all asthmatics. Patients with an “IL-17 F-high and IL5-high” profile, irrespective of expression of other cytokines, were labelled as cluster 1 (n = 24). Patients with an “IL-5-high or IL-10-high” but not an “IL-17 F-high” profile, were identified as cluster 2 (n = 16). In the next step, patients who had normal levels of the previous cytokines but were “IL-22-high”, were assigned to cluster 3 (n = 25). Patients with an “IL-6-high profile” were labelled as cluster 4 (n = 8). All other patients were grouped in cluster 5 (n = 132). *: This group consists of patients with normal levels of the previous cytokines with or without an “IL-1β- or TNF-low” profile (n = 49 and n = 83, respectively)
Fig. 4
Fig. 4
Absolute sputum cytokine levels among different clusters of steroid-naive asthmatics. Patients were clustered based on their sputum cytokine-high or cytokine-low profile. Absolute sputum cytokine levels were shown as 10–90th percentile box and whiskers plots. The dotted line represents the 10th or 90th percentile value of control individuals
Fig. 5
Fig. 5
Lung function and airway inflammatory parameters of steroid-naive asthmatics. Steroid-naive asthmatics are divided into 6 clusters: cluster I: n = 2, IL-5-high and IL-17 F-high; cluster II: n = 2, IL-5-high or IL-10-high and IL-17 F-low; cluster III: n = 5, IL-4-high; cluster IV: n = 10, IL-4-high and IL-13-high; cluster V: n = 3, IL-22-high; cluster VI: n = 20. Data are represented as mean ± standard deviation (a-b) or median ± interquartile range (c-e). FEV1% predicted levels of each cluster were compared to the mean of the total group (*: p < 0.05)

References

    1. Busse WW, Lemanske RF. Asthma. N Engl J Med. 2001;344(5):350–362. doi: 10.1056/NEJM200102013440507.
    1. Reddel HK, Bateman ED, Becker A, Boulet L-P, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):622–639. doi: 10.1183/13993003.00853-2015.
    1. Langmack EL, Martin RJ. Heterogeneity of response to asthma controller therapy: clinical implications. Curr Opin Pulm Med. 2010;16(1):13–18. doi: 10.1097/MCP.0b013e328333af9c.
    1. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875–879. doi: 10.1136/thorax.57.10.875.
    1. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. doi: 10.1038/nri3786.
    1. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. doi: 10.1164/rccm.200903-0392OC.
    1. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388–394. doi: 10.1016/j.jaci.2013.07.036.
    1. Truyen E, Coteur L, Dilissen E, Overbergh L, Dupont LJ, Ceuppens JL, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax. 2006;61(3):202–208. doi: 10.1136/thx.2005.052399.
    1. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121(3):685–691. doi: 10.1016/j.jaci.2008.01.005.
    1. Bullens D, Truyen E, Coteur L, Dilissen E, Hellings P, Dupont L, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. 2006;7(1):135. doi: 10.1186/1465-9921-7-135.
    1. Seys SF, Grabowski M, Adriaensen W, Decraene A, Dilissen E, Vanoirbeek JA, et al. Sputum cytokine mapping reveals an ‘IL-5, IL-17A, IL-25-high’ pattern associated with poorly controlled asthma. Clin Exp Allergy. 2013;43(9):1009–1017. doi: 10.1111/cea.12125.
    1. Baines KJ, Simpson JL, Wood LG, Scott RJ, Fibbens NL, Powell H, et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol. 2014;133(4):997–1007. doi: 10.1016/j.jaci.2013.12.1091.
    1. Hinks TSC, Brown T, Lau LCK, Rupani H, Barber C, Elliott S, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol. 2016;138(1):61–75. doi: 10.1016/j.jaci.2015.11.020.
    1. Marijsse GS, Seys SF, Schelpe A-S, Dilissen E, Goeminne P, Dupont LJ, et al. Obese individuals with asthma preferentially have a high IL-5/IL-17A/IL-25 sputum inflammatory pattern. Am J Respir Crit Care Med. 2014;189(10):1284–1285. doi: 10.1164/rccm.201311-2011LE.
    1. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549–556. doi: 10.1016/j.jaci.2006.01.011.
    1. Grabowski M, Seys S, Decraene A, Kasran A, Dilissen E, Barg W, et al. Airway inflammation in patients with chronic non-asthmatic cough. Thorax. 2013;68(2):125–130. doi: 10.1136/thoraxjnl-2012-201895.
    1. Seys SF, Daenen M, Dilissen E, Van Thienen R, Bullens DMA, Hespel P, et al. Effects of high altitude and cold air exposure on airway inflammation in patients with asthma. Thorax. 2013;68(10):906–913. doi: 10.1136/thoraxjnl-2013-203280.
    1. Ward JJ. Hierarchical grouping to optimize an objective function. JASA. 1963;58:236–244. doi: 10.1080/01621459.1963.10500845.
    1. Milligan G, Cooper M. An examination of procedures for determining the number of clusters in a data Set. Psychometrika. 1985;50:159–179. doi: 10.1007/BF02294245.
    1. Hinks TSC, Zhou X, Staples KJ, Dimitrov BD, Manta A, Petrossian T, et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. J Allergy Clin Immunol. 2015;136(2):323–333. doi: 10.1016/j.jaci.2015.01.014.
    1. Ferreira MA, Matheson MC, Duffy DL, Marks GB, Hui J, Le Souëf P, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011;378:1006–1014. doi: 10.1016/S0140-6736(11)60874-X.
    1. McAleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev. 2014;260(1):129–144. doi: 10.1111/imr.12183.
    1. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573–3585.
    1. Hazenberg MD, Spits H. Human innate lymphoid cells. Blood. 2014;124(5):700–709. doi: 10.1182/blood-2013-11-427781.
    1. Wawrzyniak M, Ochsner U, Wirz O, Wawrzyniak P, van de Veen W, Akdis CA, et al. A novel, dual cytokine-secretion assay for the purification of human Th22 cells that do not co-produce IL-17A. Allergy. 2016;71(1):47–57. doi: 10.1111/all.12768.
    1. Farfariello V, Amantini C, Nabissi M, Morelli MB, Aperio C, Caprodossi S, et al. IL-22 mRNA in peripheral blood mononuclear cells from allergic rhinitic and asthmatic pediatric patients. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2011;22(4):419–423. doi: 10.1111/j.1399-3038.2010.01116.x.
    1. Plé C, Fan Y, Ait Yahia S, Vorng H, Everaere L, Chenivesse C, et al. Polycyclic aromatic hydrocarbons reciprocally regulate IL-22 and IL-17 cytokines in peripheral blood mononuclear cells from both healthy and asthmatic subjects. PLoS One. 2015;10(4):e0122372. doi: 10.1371/journal.pone.0122372.
    1. Takahashi K, Hirose K, Kawashima S, Niwa Y, Wakashin H, Iwata A, et al. IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. J Allergy Clin Immunol. 2011;128(5):1067-1076-6.
    1. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61. doi: 10.1111/j.1440-1843.2006.00784.x.
    1. Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, et al. A qPCR-based metric of Th2 airway inflammation in asthma. Clin Transl Allergy. 2013;3(1):24. doi: 10.1186/2045-7022-3-24.
    1. Muraro A, Lemanske RF, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European academy of allergy and clinical immunology and the American academy of allergy, asthma & immunology. J Allergy Clin Immunol. 2016;137(5):1347–1358. doi: 10.1016/j.jaci.2016.03.010.
    1. Seys SF. Role of sputum biomarkers in the management of asthma. Curr Opin Pulm Med. 2017;23(1):34–40. doi: 10.1097/MCP.0000000000000345.

Source: PubMed

3
S'abonner